Knight Therapeutics (TSX: GUD) reported quarterly losses of $(0.03) per share which missed the analyst consensus estimate of $0.01 by 400 percent. This is a 76.92 percent increase over losses of $(0.13) per share from the same period last year. The company reported quarterly sales of $144.212 million which beat the analyst consensus estimate of $124.966 million by 15.40 percent. This is a 34.33 percent increase over sales of $107.358 million the same period last year.